Q-omics provides the consensus-scored VASN profile across patient tissues and cancer cell-line models. VASN expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, VASN is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, VASN protein abundance shows 20,648 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, KICH, and LSCC as cancer lineages where VASN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VASN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VASN survival associations across molecular data types. VASN RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VASN RNA expression–survival associations across cancer types. High VASN expression shows unfavorable associations in LUSC, MESO, BRCA and LGG, but favorable associations in HNSC and UVM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for VASN RNA expression.
This table summarizes VASN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for VASN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VASN shows lower tumor expression in KICH, BLCA and KIRP and higher tumor expression in THCA, COAD and LIHC. The KICH box plot shows higher VASN RNA expression in normal versus tumor tissue (log2 FC = −2.322, t-test p < 0.001).
This table shows molecular features associated with VASN in patient tissues and cancer cell lines. In patient samples, VASN shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, VASN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
